Learn About Cutaneous Lupus Erythematosus (CLE)

What is the definition of Cutaneous Lupus Erythematosus (CLE)?
Cutaneous lupus erythematosus is a skin condition that usually occurs in individuals with systemic lupus erythematosus (SLE) but may appear before the disease becomes systemic. Systemic lupus erythematosus is an autoimmune disease in which the immune system attacks the skin, joints, kidneys, brain, and other organs. Cutaneous lupus erythematosus is categorized into three types: chronic cutaneous lupus erythematosus (CCLE), also known as discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), and acute cutaneous lupus erythematosus (ACLE).
Save information for later
Sign Up
What are the symptoms of Cutaneous Lupus Erythematosus (CLE)?
Symptoms of chronic cutaneous lupus erythematosus, also known as discoid lupus erythematosus, are the appearance of disc-like lesions on the skin that are thick, scaly, block hair follicles, appear on skin exposed to the sun, and cause scarring. Symptoms of subacute cutaneous lupus erythematosus are the appearance of thick, scaly lesions on the skin that do not scar. Symptoms of acute cutaneous lupus erythematosus are lesions on the skin that are triggered by sun exposure.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Cutaneous Lupus Erythematosus (CLE)?
Treatment for chronic cutaneous lupus erythematosus, also known as discoid lupus erythematosus, involves avoiding sun exposure; wearing Helioplex sunscreen with an SPF of 70 or higher; corticosteroid creams, ointments, and injections; anti-malarial medications, such as Plaquenil, hydroxychloroquine, or chloroquine; and/or immunosuppressive medications. Treatment for subacute cutaneous lupus erythematosus includes the use of sunscreen, wearing protective clothing when in the sun, and avoiding sun exposure. Subacute cutaneous lupus erythematosus is often resistant to treatment with steroids or anti-malarial medications. Acute cutaneous lupus erythematosus may be treated with prednisone or other immunosuppressive drugs, such as methotrexate, cyclosporine, azathioprine, or myco-phenolate mofetil.
Who are the top Cutaneous Lupus Erythematosus (CLE) Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Cutaneous Lupus Erythematosus (CLE) Clinical Trials?
A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients With Systemic Lupus Erythematosus and Active Cutaneous Lupus Erythematosus

Summary: Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Summary: The primary objectives of the study are to evaluate the efficacy of BIIB059 compared with placebo in reducing skin disease activity measured by the Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) score [Parts A and B (US)] and the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score [Part B (ROW)] in participants with active SCLE and/...

What are the Latest Advances for Cutaneous Lupus Erythematosus (CLE)?
Centrifugal lipodystrophy on a spectrum with lupus erythematosus panniculitis in children and efficacy and safety of hydroxychloroquine: A clinicopathological study.
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Tired of the same old research?
Check Latest Advances
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.